Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance
NCT05764174 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2409
Last updated 2023-03-10
Summary
Brief Summary: The main objective of this activity is to assess the effectiveness of different messaging strategies (factual, narrative, mixed and a control) to promote COVID-19 adult vaccination.
Conditions
- Vaccination Refusal
- COVID-19
Interventions
- BEHAVIORAL
-
Factual messages
Messages with descriptive data on COVID-19 vaccines
- BEHAVIORAL
-
Narrative message
Messages with emotional descriptions on COVID-19 vaccines
- BEHAVIORAL
-
Mixed message
Messages with both descriptive data and emotional descriptions on COVID-19 vaccines
Sponsors & Collaborators
-
Pontificia Universidad Javeriana
collaborator OTHER -
Johns Hopkins Bloomberg School of Public Health
lead OTHER
Principal Investigators
-
Andres Vecino, MD PhD · Johns Hopkins Bloomberg School of Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-21
- Primary Completion
- 2022-12-17
- Completion
- 2022-12-17
Countries
- United States
Study Locations
More Related Trials
-
A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy
NCT05212935 ·Status: UNKNOWN
-
Tailoring of Vaccine-Focused Messages: Moral Foundations
NCT02851459 ·Status: COMPLETED ·Phase: NA
-
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
NCT06592794 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety of Pediatric COVID-19 Vaccination
NCT05157191 ·Status: COMPLETED
-
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
NCT06297876 ·Status: COMPLETED ·Phase: NA
-
Neurologic Manifestations of the Arbovirus Infection in Colombia
NCT03206541 ·Status: COMPLETED
-
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
NCT05193279 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
NCT00474526 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Inactivated COVID-19 Vaccine of the First Booster Dose
NCT05367895 ·Status: UNKNOWN
-
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
NCT01345721 ·Status: COMPLETED ·Phase: PHASE3
-
Vaccine Attitudes and Practices of Hospital Specialists
NCT03403114 ·Status: COMPLETED
-
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 Patients Vaccinated With MenBVac® (Extension MenbVac)
NCT01565577 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination
NCT05545683 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
NCT00450437 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine
NCT01897402 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
NCT00474487 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of a Typhoid Conjugate Vaccine in DRC
NCT05119426 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
NCT00560313 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
NCT00616421 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
NCT00310817 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03691610 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837 ·Status: COMPLETED ·Phase: PHASE3
-
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
NCT00381615 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
NCT00626327 ·Status: COMPLETED ·Phase: PHASE3